SP-333: Phase II started

Synergy began a double-blind, placebo-controlled Phase II trial to evaluate 1, 3 and 6 mg oral SP-333 once daily for 4 weeks in about 260 OIC patients taking opioid analgesics for chronic, non-cancer ...